Pharmaceutical significance of amorphous materials;Amorf anyagok gyógyszerészeti jelentösége

Acta Pharmaceutica Hungarica

Volumn 78, Issue 3, 2008, Pages 121-133

  István, Antal ^a   Romána, Zelkó ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMORPHOUS MATERIAL; ARTICLE; BIOAVAILABILITY; DISSOLUTION; ENERGY; MATERIALS; PHYSICAL CHEMISTRY; SOLID STATE; SOLUBILITY;

BIOLOGICAL AVAILABILITY; CRYSTALLOGRAPHY; DRUG STABILITY; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL; THERMODYNAMICS;

EID: 55349106585     PISSN: 00016659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Byrn, S. R., Pfeiffer, R. R., Stoweil, J. G. Solid state chemistry of drugs. West Lafayette, SSCI Inc. (1999).
2. Aguiar, A.J.; Krc, J. Jr.; Kinkel, A.W.; Samyn, J.C.: Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. Journal of Pharmaceutical Sciences, 56, 847-853. (1967).
3. Mullins, J.; Macek, T. Some pharmaceutical properties of novobiocin. Journal of American Pharmaceutical Association (Sci. Ed.) 49, 245-248. (1960).
4. Haleblian, J.K.: Characterisation of habits and crystalline modifications of solids and their pharmaceutical applications. Journal of Pharmaceutical Sciences, 64, 1269-1288. (1975).
5. Vippagunta, S.R.; Brittain, H.G.; Grant, D.J.: Crystalline solids. Advanced Drug Delivery Reviews. 48, 3-26. (2001).
6. Byrn, S.; Pfeiffer, R.; Ganey, M.; Hoiberg, C.; Poochikiam, G.: Pharmaceutical solids: A strategic approach to regulatory considerations. Pharmaceutical Research. 12, 945-954. (1995).
7. Agrawal, S.; Ashokraj, Y.; Bharatam, P.V.; Pillai, O.; Panchagnula, R.: Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. European Journal of Pharmaceutical Sciences, 22, 127-44. (2004)
8. Kaushal, A.M.; Gupta, P.; Bansal, A.K.: Amorphous drug delivery systems: molecular aspects, design, and performance. Critical Reviews in Therapeutic Drug Carrier Systems. 21, 133-193. (2004).
9. Petit, S.; Coquerel, G.: The Amorphous State, in Hilfiker, R. (Ed.) Polymorphism: in the Pharmaceutical Industry (1st). Weinheim, Wiley-VCH Verlag, pp. 259-285. (2006).
10. Shalaev, E.; Shalaeva, M.; Zografi, G.: The effect of disorder on the chemical reactivity of an organic solid, tetraglycine methyl ester: change of the reaction mechanism. Journal of Pharmaceutical Sciences, 91, 584-593. (2002).
11. Hancock, B. C.; Zografi, G.: Characteristics and significance of the amorphous state in pharmaceutical systems. Journal of Pharmaceutical Sciences, 86, 1-12. (1997).
12. Hilden, L.R.; Morris, K.R.: Physics of amorphous solids. Journal of Pharmaceutical Sciences, 93, 3-12. (2004).
13. Angell, C.A.: The old problems of glass and the glass transition, and the many new twists. Proceedings of the National Academy of Sciences of the United States of America. 92, 6675-6682. (1995).
14. Kaushal, A.M.; Bansal, A.K.: Thermodynamic behavior of glassy state of structurally related compounds. European Journal of Pharmaceutics and Biopharmaceutics. (doi:10.1016/j.ejpb.2008.02.001) (2008).
15. Kauzmann, W. The nature of the glassy state and the behavior of liquids at low temperatures. Chemical Reviews. 43, 219-256. (1948).
16. Hancock, B.C.; Shamblin, S.L.; Zografi, G.: Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharmaceutical Research. 12, 799-806. (1995).
17. Carstensen, J.T.: Advanced Pharmaceutical Solids, New York, Marcel Dekker, Inc., pp. 107-116. (2001).
18. Angell, C.A.: Formation of glasses from liquids and biopolymers. Science. 267, 1924-1935. (1995).
19. Jolley, J.E.: Microstructure of photographic gelatin binders. Photographic Scientific Engineering. 14, 169-177. (1970).
20. Saleki-Gerhardt, A.; Ahlneck, C.; Zografi, G.: Assessment of disorder in crystalline solids. International Journal of Pharmaceutics. 201, 237-247. (1994).
21. Gordon, M., Taylor, J.S.: Ideal co-polymers and the second order transitions of synthetic rubbers. I. Non-crystalline copolymers. J. Appl. Chem. 2, 493-500. (1952).
22. Hancock, B.C.; Parks, M.: What is the true solubility advantage for amorphous pharmaceuticals? Pharmaceutical Research. 27, 397-404. (2000).
23. Shamblin, S.L.; Tang, X.; Chang, L.; Hancock, B.C.; Pikal, M.J.: Characterization of the time scales of molecular motion in pharmaceutically important glasses. Journal of Physical Chemistry B. 203, 4113-4121. (1999).
24. Amidon, G. L.; Lennernas, H.; Shah, V.P.; Crison, J.R.: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research. 12, 413-420. (1995).
25. Yalkowski, S.H.: Solubility and Solubilization in Aqueous Media. Oxford, Oxford University Press, pp. 81-115. (1999).
26. Brittain, H.G.: Polymorphism in Pharmaceutical Solids, New York, Marcel Dekker, Inc. (1999).
27. Singhal, D.; Curatolo, W.: Drug polymorphism and dosage form design: a practical perspective. Advanced Drug Delivery Reviews, 56, 335-347. (2004).
28. Hancock, B.C.: Disordered drug delivery: destiny, dynamics and the Deborah number. Journal of Pharmacy and Pharmacology. 54, 737-746. (2002).
29. Rodríguez-Spong, B.; Price, C.P.; Jayasankar, A.; Matzger, A.J.; Rodríguez-Hornedo, N.: General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Advanced Drug Delivery Reviews. 23, 241-274. (2004).
30. Byrn, S.R.; Xu, W.; Newman, A.W.: Chemical reactivity in solid-state pharmaceuticals: formulation implications. Advanced Drug Delivery Reviews. 48, 115-136. (2001).
31. Guo. Y; Byrn, S.R.; Zografi, G.: Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. Journal of Pharmaceutical Sciences 89, 128-143. (2000).
32. Andronis, V.; Yoshioka, M.; Zografi, G.: Effects of sorbed water on the crystallization of indomethacin from the amorphous state. Journal of Pharmaceutical Sciences 86, 346-351. (1997)
33. Airaksinen, S.; Karjalainen, M.; Shevchenko, A.; Westermarck, S.; Leppänen, E.; Rantanen, J.; Yliruusi, J.: Role of water in the physical stability of solid dosage formulations. Journal of Pharmaceutical Sciences, 94, 2147-65. (2005).
34. Elamin, A. A.; Alderborn, G.; Ahlneck, C.: The effect of pre-compaction processing and storage conditions on powder and compaction properties of some crystalline materials, International Journal of Pharmaceutics. 208, 213-224. (1994).
35. Zhang, G.G.; Law, D., Schmitt, E.A.; Qiu, Y.: Phase transformation considerations during process development and manufacture of solid oral dosage forms. Advanced Drug Delivery Reviews. 56, 371-90. (2004).
36. Aso, Y.; Yoshioka, S.; Kojima, S.: Relationship between the crystallization rates of amorphous nifedipine, phenobarbital, and flopropione, and their molecular mobility as measured by their enthalpy relaxation and (I)H NMR relaxation times. Journal of Pharmaceutical Sciences, 89, 408-416. (2000).
37. Rogers, T.L.; Johnston, K.P.; Williams, R.O.: Solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid CO2 and cryogenic spray-freezing technologies. Drug Development and Industrial Pharmacy. 27, 1003-1015. (2001).
38. Tang, X.; Pikal, M.J.: Design of freeze-drying processes for pharmaceuticals: practical advice. Pharmaceutical Research. 21, 191-200. (2004).
39. Takeuchi, H.; Nagira, S.; Yamamoto, H.; Kawashima, Y.: Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. International Journal of Pharmaceutics. 293, 155-164. (2005).
40. Elamin, A.A.; Ahlneck, C.; Alderborn, G.; Nyström, C.: Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. International Journal of Pharmaceutics. 111, 159-170. (1994).
41. Forster, A.; Hempenstall, J.; Rades, T.: Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. Journal of Pharmacy and Pharmacology. 53, 303-315. (2001).
42. Leuner, C.; Dressman, J.: Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics. 50, 47-60. (2000).
43. Ambike, A.A.; Mahadik, K.R.; Paradkar, A.: Stability study of amorphous valdecoxib. International Journal of Pharmaceutics. 282, 151-162. (2004).
44. Breitenbach. J.: Melt extrusion: from process to drug delivery technology. European Journal of Pharmaceutics and Biopharmaceutics. 54. 107-117. (2002)
45. Abdul-Fattah, A.M.; Truong-Le, V.; Yee, L.; Pan, E.; Ao Y.; Kalonia, D.S.; Pikal, M.J.: Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine. Pharmaceutical Research. 24, 715-727. (2007).
46. Carpenter, J.R; Pikal, M.J.; Randolph, T.W.: Rational design of stable lyophilized protein formulations: Some practical advice. Pharmaceutical Research. 14, 969-975. (1997).
47. White, S.; Bennett, D.B.; Cheu, S.; Conley, P.W.; Guzek, D.B.; Gray, S.; Howard, J.; Malcolmson, R.; Parker, J.M.; Roberts, P.; Sadrzadeh, N.; Schumacher, J.D.; Seshadri, S.; Sluggett, G.W.; Stevenson, C.L.; Harper, N.J.: EXUBERA®: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technology & Therapeutics. 7, 896-906. (2005).
48. Hancock, B.C.; Carlson, G.T.; Ladipo, D.D.; Langdon, B.A.; Mullarney, M.P.: Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. International Journal of Pharmaceutics. 241, 73-85. (2002).
49. Ahlneck, C.; Zografi, G.: The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. International Journal of Pharmaceutics. 62, 87-95. (1990).
50. Imaizumi, H.; Nambu, N.; Nagai, T.: Stability and several physical proper-ties of amorphous and crystalline forms of indomethacin. Chemical & Pharmaceutical Bulletin. 28, 2565-2569. (1980).
51. Sebhatu, T.; Ahlneck, C.; Alderborn, G.: The effect of moisture content on the compression and bond-formation properties of amorphous lactose particles. International Journal of Pharmaceutics. 146, 101-114. (1997).
52. Nakai, Y.; Yamamoto, K.; Terada, K.; Kajiyama, A.: Relationships between crystallinity of -cyclodextrin and tablet characteristics. Chemical & Pharmaceutical Bulletin. 33, 5110-5112. (1985).
53. Newell, H.E.; Buckton, G.; Butler, O.A.; Thielmann, F.; Williams, D.R.: The use of inverse phase gas chromatography to study the change of surface energy of amorphous lactose as a function of relative humidity and the processes of collapse and crystallisation. International Journal of Pharmaceutics. 217, 45-56. (2001).
54. Dilworth. S-E-; Buckton, G.; Gaisford, S.; Ramos, R.: Approaches to determine the enthalpy of crystallisation, and amorphous content, of lactose from isothermal calorimetric data. International Journal of Pharmaceutics. 284, 83-94. (2004).
55. Haleblian, J.K.: Characterization of habits and crystalline modification of solids and their pharmaceutical applications. Journal of Pharmaceutical Sciences, 64, 1269-1288. (1975).
56. Byrn, S.; Pfeiffer, R.; Ganey, M.; Hoiberg, C.; Poochikiam, G.: Pharmaceutical solids: A strategic approach to regulatory considerations. Pharmaceutical Research. 12, 945-954. (1995).
57. Gao, D.; Maurin, M.B.: Physical chemical stability of warfarin sodium. AAPS PharmSci. 3, 1-8. (2001).
58. Révész, P.: Amorf anyagok szerepe a gyógyszeriparban. In: Kristályosítástól a tablettázásig (Szerk.: Farkas B., Révész P.), Universitas Szeged Kiadó, Szeged, p. 247-266, 2007.
59. Niazi S.K.: Handbook of Preformulation, New York, Informa Healthcare, Inc., pp. 197-239. 2007.
60. Liu, J.; Rigsbee, D.R.; Stotz, C.; Pikal, M.J.: Dynamics of pharmaceutical amorphous solids: the study of enthalpy relaxation by isothermal microcalorimetry. Journal of Pharmaceutical Sciences, 91, 1853-1862. (2002).
61. Kalász, H.; Antal, I.: Drug excipients. Current Medicinal Chemistry, 13, 2535-2563. (2006).
62. Loftsson, T.; Jarho, P.; Masson, M.; Järvinen T.: Cyclodextrins in drug delivery. Expert Opinion on Drug Delivery, 2, 335-351 (2005).
63. Larhrib, H.; Zeng, X.M.; Martin, G.P.; Marriott, C.; Pritchard, J.: The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. International Journal of Pharmaceutics, 191, 1-14. (1999).
64. Narasimhan, B.: Mathematical models describing polymer dissolution: consequences for drug delivery. Advanced Drug Delivery Reviews, 48, 195-210. (2001).
65. Zelkó, R.; Süvegh, K.: Correlation between the release characteristics of theophylline and the free volume of polyvinylpirrolidone. European Journal of Pharmaceutical Sciences, 24, 351-354. (2005).
66. Wunderlich, B.: Crystal Melting: Macromolecular Physics. Vol 3. New York, Academic Press. 1980.
67. Kiss, D.; Süvegh, K.; Marek, T.; Dévênyi, L.; Novák, Cs.; Zelkó, R.: Tracking the physical aging of poly(ethylene oxide) - A technical note. AAPS PharmSciTech, 7(4), Article 95. DOI:10.1208/pt070495 (2006)
68. Antal, I.; Zelkó, R. (megjelenés alatt): Significance of the amorphous state - A pharmaceutical approach. In: Amorphous Materials: Research, Technology and Applications. Nova Science Publishers, Inc., Hauppauge, NY.